A Phase 2 interventional study of RVT-1401 680 mg/weekly and RVT-1401 340 mg/weekly in Warm Autoimmune Hemolytic Anemia, sponsored by Immunovant Sciences GmbH. Terminated at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-28.
Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.
This is a Phase 2, non-randomized, sequential, open-label study to investigate the safety, tolerability, PK, PD, and efficacy of RVT-1401 (680 mg/weekly and 340 mg/weekly) in patients with Warm Autoimmune Hemolytic Anemia that is worsening or refractory in spite of therapy with steroids and or immunosuppressants or worsening with steroid or immunosuppressant taper. Two cohorts of participants will be enrolled in a non-randomized sequential approach. Participants will be enrolled into Cohort 1 (680 mg/weekly) first followed by Cohort 2 (340 mg/weekly).
Following the initial dose at the Baseline Visit (Week 1, Day 1), study visits will occur weekly throughout the treatment period. Following the final dose at Week 12, visits will occur weekly through Week 14 and then at Week 16 and Week 20. Safety, PK, PD, and clinical assessments will be collected throughout the study.
Each participant will participate in the study for up to approximately 24 weeks: up to a 4-week screening period, a 12-week treatment period, and an 8-week follow up period.
103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.
This study's enrollment of 5 is below the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.
Browse Anemia, Hemolytic, Autoimmune studies →Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is of:
Other, more specific inclusion criteria are defined in the protocol.
Exclusion Criteria:
Other, more specific exclusion criteria are defined in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
Drug: RVT-1401 680 mg/weekly
Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
Drug: RVT-1401 340 mg/weekly
Number of Responders at Week 13
Responders were defined as the participants with level of hemoglobin (Hb) \>=10 grams per deciliter (g/dL) with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous two weeks.
Time frame: Week 13
Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death
AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Clinically significant changes determined by the Investigator such as vital signs, Electrocardiograms (ECGs), and clinical laboratory values were also reported as AEs. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
Time frame: Up to Week 20
Time to Response
The time to response was defined as the amount of time to achieve response (Hb levels \>=10 g/dL with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous 2 weeks).
Time frame: Up to Week 13
Time to Achieving Hb Levels in the Normal Range
Time to achieving Hb levels in the normal range was assessed.
Time frame: Up to Week 13
Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score
The FACIT-F scale was a validated scale which measured the physical, emotional and social implications of fatigue, one of the key clinical manifestations of warm autoimmune hemolytic anemia. Scores ranged from 0-52, a higher score indicated a higher quality of life. A score of less than 30 indicated severe fatigue. The scale took approximately 5-10 minutes to complete.
Time frame: Up to Week 13
Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale
The MRC Breathlessness scale is a questionnaire that consisted of 5 statements about perceived Breathlessness and the focus of the scale was to quantify the disability associated with breathlessness. Score ranged from Grade 0 (limited to no disability) to Grade 4 (severe disability); higher score indicated severe disability.
Time frame: Up to Week 13
Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score
The EQ-5D-3L is a validated measurement of health-related quality of life. The scale consists of 2 components, the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems; a lower score indicated better quality of life. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0).
Time frame: Up to Week 20
Concentration of RVT-1401 Pre-dose
Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic (PK) RVT-1401.
Time frame: Pre-dose, Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12 and 13 post-dose
Number of Participants With Presence of Anti-RVT 1401 Antibodies
Blood samples were collected at indicated time points to determine presence of anti-RVT 1401 antibodies. Participants with presence of anti-RVT 1401 antibodies is reported
Time frame: Pre-dose on Weeks 1, 3, 5, 8, 13 and Week 20
Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4)
Blood samples were collected at indicated time points for pharmacodynamic (PD) analysis of serum total IgG and IgG subclasses (1-4) concentrations. Participants with changes in levels of Total IgG and IgG Subclasses (1-4) is reported.
Time frame: Up to Week 20
| Milestone | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Started | 5 | 0 |
| Completed | 2 | 0 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Safety concerns | 1 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 |
Responders were defined as the participants with level of hemoglobin (Hb) \>=10 grams per deciliter (g/dL) with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous two weeks.
| Participants | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Number of Responders at Week 13 | 1 | — |
AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Clinically significant changes determined by the Investigator such as vital signs, Electrocardiograms (ECGs), and clinical laboratory values were also reported as AEs. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
| Participants | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| TEAEs | 5 | — |
| SAEs | 1 | — |
| Treatment-related AEs | 4 | — |
| Deaths | 0 | — |
The time to response was defined as the amount of time to achieve response (Hb levels \>=10 g/dL with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous 2 weeks).
| Weeks | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Time to Response | 3 | — |
Time to achieving Hb levels in the normal range was assessed.
| Weeks | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Time to Achieving Hb Levels in the Normal Range | 5 | — |
The FACIT-F scale was a validated scale which measured the physical, emotional and social implications of fatigue, one of the key clinical manifestations of warm autoimmune hemolytic anemia. Scores ranged from 0-52, a higher score indicated a higher quality of life. A score of less than 30 indicated severe fatigue. The scale took approximately 5-10 minutes to complete.
| Participants | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score | 3 | — |
The MRC Breathlessness scale is a questionnaire that consisted of 5 statements about perceived Breathlessness and the focus of the scale was to quantify the disability associated with breathlessness. Score ranged from Grade 0 (limited to no disability) to Grade 4 (severe disability); higher score indicated severe disability.
| Participants | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale | 4 | — |
The EQ-5D-3L is a validated measurement of health-related quality of life. The scale consists of 2 components, the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems; a lower score indicated better quality of life. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0).
| Participants | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score | 4 | — |
Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic (PK) RVT-1401.
| Milligrams per liter | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Concentration of RVT-1401 Pre-dose | NA ± NA | — |
Blood samples were collected at indicated time points to determine presence of anti-RVT 1401 antibodies. Participants with presence of anti-RVT 1401 antibodies is reported
| Participants | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Number of Participants With Presence of Anti-RVT 1401 Antibodies | 0 | — |
Blood samples were collected at indicated time points for pharmacodynamic (PD) analysis of serum total IgG and IgG subclasses (1-4) concentrations. Participants with changes in levels of Total IgG and IgG Subclasses (1-4) is reported.
| Participants | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Total IgG | 5 | — |
| IgG Subclasses (1-4) | 5 | — |
Collected over All-cause mortality, non-serious TEAEs and SAEs were collected up to Week 20 in Cohort 1.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Cohort 2: RVT-1401 340 mg/Week | — | — | — |
| Event | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| Immune thrombocytopeniaBlood and lymphatic system disorders | 1/5 | — |
| Event | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week |
|---|---|---|
| HypoalbuminaemiaMetabolism and nutrition disorders | 3/5 | — |
| Oedema peripheralGeneral disorders | 2/5 | — |
| FatigueGeneral disorders | 2/5 | — |
| RhinitisInfections and infestations | 1/5 | — |
| ParaesthesiaNervous system disorders | 1/5 | — |
| Non-cardiac chest painGeneral disorders | 1/5 | — |
| CataractEye disorders | 1/5 | — |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/5 | — |
| NauseaGastrointestinal disorders | 1/5 | — |
| HypocalcaemiaMetabolism and nutrition disorders | 1/5 | — |
Safety Population: all participants who received at least one dose of study treatment. Only data for Cohort 1 is presented as study was terminated early prior to completion of dosing all participants in Cohort 1 and and Cohort 2 was not initiated.
| Age, Categorical(Participants) | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 0 | 4 |
| >=65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week | Total |
|---|---|---|---|
| Female | 3 | 0 | 3 |
| Male | 2 | 0 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 0 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Apr 2021, 7 months.
Results were first posted in Jul 2022, 1 year 3 months after primary completion. A results delay was requested in Mar 2022.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HBM9161
Anemia, Hemolytic, Autoimmune →
Immunovant Sciences GmbH